Nymox Pharmaceutical Corporation NYMXF
OTC PK
| 12/31/2024 | 12/31/2023 | ||||
|---|---|---|---|---|---|
| Net Income | -- | -412.64% | |||
| Total Depreciation and Amortization | -- | -74.77% | |||
| Total Amortization of Deferred Charges | -- | -- | |||
| Total Other Non-Cash Items | -- | 43,757.14% | |||
| Change in Net Operating Assets | -- | 357.71% | |||
| Cash from Operations | -- | 28.98% | |||
| Capital Expenditure | -- | -- | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | -- | -- | |||
| Cash from Investing | -- | -- | |||
| Total Debt Issued | -- | 200.00% | |||
| Total Debt Repaid | -- | 79.07% | |||
| Issuance of Common Stock | -- | -85.00% | |||
| Repurchase of Common Stock | -- | -- | |||
| Issuance of Preferred Stock | -- | -- | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | -- | -- | |||
| Cash from Financing | -- | -26.18% | |||
| Foreign Exchange rate Adjustments | -- | -- | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | -- | 89.29% | |||